Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie's next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease. The 4R tau PET imaging biomarkers hold great promise as important new tools in advancing the understanding of neurodegenerat.

Enigma Biomedical Group - USA Signs License Agreement with AbbVie for Novel 4R Tau PET Imaging Biomarkers

ST. LOUIS--(BUSINESS WIRE)--SHARx Files Defamation and Deceptive Business Practices Suit Against AbbVie.

SHARx Files Defamation Suit Against AbbVie

In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.

AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note

Health Care Select Sector SPDR Fund

Danaher

DexCom

Eli Lilly

McKesson

UnitedHealth Group

Viatris

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.

Charts turn bullish on health-care stocks as sector takes early lead in 2024

Abbott Labs

AbbVie launched about a decade ago as Abbott's spinoff of its pharmaceuticals business. Both companies have since lifted earnings into the triple digits.

Better Growth Stock: Abbott vs. AbbVie

Federal Realty Investment Trust

Leggett & Platt

Altria

Northwest Natural Gas

Universal Corp

Altria owns over 10% of Anheuser-Busch InBev (NYSE: BUD), the world's largest brewer.

The 7 Highest Yielding 2024 Dividend Kings To Buy and Hold Forever

Amazon

Booking Hlds

Americans are increasingly interested in investing -- a great thing! It's important to set goals, and seeing these benchmarks can help.

Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today

American Tower

Ares Capital

Bristol-Myers

BlackRock Science & Technology

Central Securities

Chevron

Enbridge

Home Depot

Intuit

JPMorgan Equity Premium Income ETF

Barings Corporate Investors

Medtronic

MPLX

Morgan Stanley

Microsoft

NextEra Energy

NXP Semiconductors

Realty Income Corp

PepsiCo

Parker-Hannifin

Regions Financial

Cohen & Steers Quality Income Realty Fund

Schwab US Dividend Equity ETF

Columbia Seligman Premium Technology Growth Func Inc

We outline an Income Strategy for creating a self-sufficient portfolio for retirees and income-focused investors with $1 million to generate a life-long income stream. We explain the benefits of generating income through dividends and distributions rather than selling shares for capital gains. We compare the results of backtesting an income strategy with index investing for the past 24 years, starting from the year 2000.

How To Invest $1 Million In Retirement For Life-Long Income

After underperforming the broad market over the past year, shares of Medtronic offer a 3.4% dividend yield. AbbVie shares offer a juicy 3.8% dividend yield even though the payout has grown 287% over the past 10 years.

2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade

Amcor Plc

Air Products and Chemicals

Franklin Resources

Cincinnati Financial

Genuine Parts

Johnson & Johnson

Coca-Cola

T. Rowe Price Group

Walgreens

Exxon Mobil

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.

3 Dividend Aristocrats Signal Buy In January With 7 To Watch

AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference

AbbVie expects its share of Botox in the aesthetics market to remain strong in the fourth quarter, despite recent launches of newer, longer-acting products by rival companies, the company's executive said on Wednesday.

AbbVie expects Botox market share to stay strong despite newer rivals

Apple

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Colgate-Palmolive

Canadian Imperial Bank of Commerce

The S&P500 delivered a strong year-end rally, gaining 4.5% in December and 26.3% for the year.

My Dividend Stock Portfolio: New December Dividend Record - 98 Holdings With 18 Buys

News for AbbVie Stock (ABBV)